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Summary
Background: The diagnosis of either Alzheimer’s disease (AD) or vascular dementia 
(VaD) is still largely based on clinical guidelines and exclusion of other diseases that 
may lead to dementia.
Aims: In this study, we assessed whether the use of sensitive and specific biomarkers 
such as phosphorylated tau proteins could contribute to an earlier and more accurate 
diagnosis of AD and VaD, as well as to their differentiation.
Material and methods: A total of 198 patients, of which 152 had AD, 28 VaD, and 18 
were healthy controls (HC), were included in the analyses. We analyzed cerebrospinal 
fluid (CSF) levels of total tau protein (t-tau), tau protein phosphorylated at threonine 
231 (p- tau231), and factor score (FS) determined by combination of p- tau231 and Mini- 
Mental State Examination (MMSE) in patients with AD and VaD, as well as in HC. We 
tested the diagnostic accuracy of these biomarkers in the CSF and FS (p- tau231, MMSE) 
in differentiating AD from VaD and HC.
Results: Total tau levels were significantly elevated in subjects with AD compared to 
HC, as well as in VaD subjects compared to HC.
Discussion: p- tau231 levels were significantly higher in patients with AD vs HC as well 
in patients with VaD vs HC. p- tau231 levels did not distinguish AD from VaD patients. 
Importantly, FS(p- tau231 and MMSE) showed statistically significant differences in the 
distribution of subjects with AD and VaD.
Conclusion: These results indicate that FS (p- tau231 and MMSE) has a strong 
potential to provide an early distinction between AD and VaD.
K E Y W O R D S
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1  | INTRODUCTION
Dementia is a major public health problem worldwide, partly due to the 
increasing life expectancy of the population. Epidemiological data for 
developed countries show that the prevalence of Alzheimer’s disease 
(AD) in adults at age 60- 64 is less than 1% in Europe, but after age 65, 
the incidence doubles every 5 years of life.1,2 Overall, neurological dis-
eases that cause dementia are the third leading cause of life with dis-
abilities globally.3 The most common primary cause of dementia is AD,4 
which represents over 65% of all dementia cases, followed by vascular 
dementia (VaD), which is responsible for most of the remainder.4 AD 
is characterized by an insidious onset with a slow progressive course 
with impairment of memory, language, and visuospatial functions ul-
timately resulting in global cognitive impairment.5 VaD represents a 
large group of clinical entities associated with vascular changes6 and 
heterogeneous clinical presentation described as less insidious in onset 
compared to AD, which shows a stepwise decline in cognitive abilities.7 
The most important feature of VaD is that it can be prevented by acting 
on risk factors, stressing the need for an early diagnosis of VaD.6
Diagnosis of either AD or VaD is still largely based on clinical guide-
lines and exclusion of other diseases that may lead to dementia. For AD, 
we used diagnostic criteria of McKhann and collaborators from 2011.7 
Compared to the older AD criteria from 1984,8 which addressed only 
one final stage of the disease and memory loss as the first and only 
major symptom, these new criteria recognize preclinical stage, middle 
stage of mild cognitive impairment (MCI), and final stage of AD marked 
by symptoms of dementia, and also take into account that other as-
pects of cognition may become impaired first. They also recognize the 
potential use of both imaging and biochemical biomarkers to help di-
agnose AD. For VaD, we used the National Institute for Neurological 
Disorders and Stroke- Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (NINCDS- AIREN) criteria for prob-
able VaD,9 as well as the Hachinski Ischemic Score (HIS).10 The most 
important clinical discriminative factors for VaD vs AD are stepwise 
progression, prominent impairment of the executive functions, HIS > 4, 
and focal neurological signs implying cortical or subcortical lesions.11
The use of sensitive and specific biomarkers such as tau proteins, 
especially phosphorylated tau proteins, could contribute to the ear-
lier and more accurate diagnosis of both AD and VaD.12 In this study, 
we analyzed cerebrospinal fluid (CSF) levels of total tau protein (t- tau) 
and tau protein phosphorylated at threonine 231 (p- tau231) in patients 
with AD and VaD, as well as in healthy controls (HC), to assess the 
diagnostic accuracy of these biomarkers in the CSF in differentiation 
of AD from VaD and HC.
2  | PATIENTS AND METHODS
2.1 | Patients
Patients who met all inclusion criteria were invited to participate in 
the study. The patients were examined at two study site, General 
Hospital Varaždin and Clinical Hospital Center Rebro Zagreb from 
August 2011 until May 2015.
At the initial visit, the patients signed an informed consent form. 
Consent form was explained in details to patients and caregiver. 
Patient and caregiver gave consent to participate in the study as 
well as to perform lumbar puncture. The possible complications of 
the procedure were explained in detail. All procedures involving 
human subjects were performed with the approval of the Central 
Ethical Committee of the University of Zagreb Medical School, case 
no. 380- 59/11- 500- 77/90, class 641- 01/11- 02. This research 
study had exclusively a diagnostic purpose and was not evaluating 
any health- related interventions to evaluate possible effects on 
health outcomes. As such, it has not been registered as a clinical 
trial. Two hundred patients were assessed. Two patients were not 
included in the study because of pathological findings on magnetic 
resonance (MR) scan of the brain. The study included 198 patients, 
of which 152 patients with AD, 28 patients with VaD, and 18 HC. 
For AD, we used diagnostic criteria of McKhann and collaborators 
from 2011.7 For VaD, the patients fulfilled NINCDS- AIREN9 and 
HIS criteria.10 The following inclusion criteria were used: age be-
tween 50 and 90 years, anamnestic data suspicious of developing 
dementia, normal neurological status or the presence of focal pyra-
midal or cerebellar lesion, Mini- Mental State Examination (MMSE) 
27- 15, neuropsychological testing suspected to dementia syn-
drome (Montreal Cognitive Assessment, MoCA, Alzheimer’s Disease 
Assessment Scale- cognitive subscale, ADAS- Cog), complete blood 
tests including levels of vitamin B12, folic acid (B9) and thyroid func-
tion test, a negative serology for syphilis or Lyme’s disease, and ab-
sence of other pathologies on brain MR imaging. Patients who did 
not fulfill these criteria were excluded from the study. It should be 
noted that HIS only suggests the likelihood of VaD, but does not 
confirm the presence or absence of VaD and that neuroradiologic 
diagnosis remains unreliable in the early phase of the disease.
2.2 | Cerebrospinal fluid (CSF) sampling and analysis
Lumbar puncture was performed between 8 am and 10 am, and CSF 
was obtained by a routine protocol from the L3/L4 or L4/L5 interver-
tebral space. After the first few drops were discharged, 2 mL of the 
CSF was collected in polypropylene tubes. In case of a traumatic 
puncture with hemorrhagic CSF, these samples were excluded from 
analysis. CSF samples were stored at 4°C, wrapped in aluminum 
foil, and transported on ice to the laboratory. All enzyme- linked 
immunosorbent assay (ELISA) analyses of CSF samples were per-
formed at the Laboratory for Developmental Neuropathology of the 
Croatian Institute for Brain Research, University of Zagreb School 
of Medicine. Each sample was first centrifuged for 10 minutes at 
2000 g at 4°C to exclude cells and other insoluble materials. The 
remaining amount of CSF was stored at −80°C for later analysis of 
CSF biomarkers. All CSF analyses were performed according to the 
manufacturers’ detailed instructions, with at least two internal sam-
ple controls used to verify the consistency of the results. The total 
tau protein concentration (all 6 isoforms) was determined using 
human Tau Ag Fujirebio (Ghent, Belgium) ELISA kit. To determine 
the concentration of tau protein phosphorylated at threonine 231 
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(p- tau231), the Tau [pT231] (Phospho) Human ELISA Kit (Thermo 
Fisher Scientific, Waltham, MA, USA) was used. Results were read 
using an ELISA Reader Model Bio- Rad 680 (Bio- Labor Laboratories, 
Hercules, CA, USA). There were no significant differences in the 
levels of total tau and p- tau231 between the samples from the two 
different hospitals (Zagreb and Varaždin).
2.3 | Statistical analysis
For comparison of demographic, clinical, and laboratory parameters, 
the nonparametric Kruskal- Wallis test was used. Due to the relatively 
small sample sizes and because it does not require assumption of nor-
mal distributions, the nonparametric Mann- Whitney U test was used 
for some comparisons between the groups, in addition to the t test. 
Receiver operating characteristic (ROC) curve analysis was used to 
evaluate the diagnostic value of the parameters from the variables 
in the differentiation of the examined groups. Cut-off levels of both 
markers used in the study were derived from the ROC curve analysis, 
with the sum of sensitivity and specificity maximized. In addition, the 
specificity of both markers in differentiating the groups, with sensitiv-
ity set to 85%, was determined. Sensitivity and specificity were visual-
ized with confidence interval (CI) of 95%. In addition, the area under 
the ROC curve (AUC) was shown as an accuracy indicator. The cor-
relation between CSF biomarkers was tested using the Spearman test 
(rs) and the Pearson coefficient of correlation (r). The factor score (FS) 
was used as a multidimensional analysis method that describes rela-
tionship of a large number of original variables by means of a smaller 
number of common factors or by a variable that better describes 
them, or explain their relationship more clearly. The factor score of 
p- tau231 and MMSE was determined using the dimension reduction 
option in SPSS. With this function, two or more variables (so- called 
manifest variables) are unified into one (factor score or so- called la-
tent variable).
3  | RESULTS
The demographic data of the subjects included in the study, their 
MMSE scores, and CSF levels of t- tau and p- tau231 are shown in 
Table 1. On average, patients with AD (U = 635, Z = −3.437, P = 0.001) 
and VaD patients (U = 132, Z = −2.484, P = 0.013) were significantly 
older than HC.  However, because there was no significant correlation 
between age and CSF biomarker levels, the lower mean age of the HC 
was not considered as a significant factor in the interpretation of the 
results. Patients with AD (U = 57.5, Z = −6.065, P < 0.001) and VaD 
patients (U = 41, Z = −4.334, P < 0.001) had significantly lower MMSE 
scores in comparison to HC. Levels of t- tau were significantly higher in 
AD patients in comparison to HC (U = 654, Z = −3.616, P < 0.001) and 
VaD patients in comparison to HC (U = 124, Z = −2.881, P = 0.004).
The levels of p- tau231 were significantly higher in AD (U = 548, 
Z = −4.030, P < 0.001) and VaD patients (U = 79.5, Z = −2.940, 
P = 0.003) in comparison to HC (Figure 1).
The factor score values for p- tau231 and MMSE, FS (p- tau231, 
MMSE), were significantly lower in AD (U = 71, Z = −5.946, P < 0.001) 
and VaD patients (U = 39, Z = −3.700, P < 0.001) in comparison to 
HC. The FS (p- tau231, MMSE) was significantly lower in AD (U = 760, 
Z = −3.417, P = 0.001) in comparison to VaD patients (Figure 2).
Also, p- tau231 levels positively and significantly correlated with the 
levels of t- tau (Table 2, Figure 3). ROC curve analyses of AD vs HC and 
VaD vs HC were significant for p- tau231, as well as when comparing FS 
(p- tau231, MMSE) in AD vs HC, VaD vs HC, and AD vs VaD (Figure 4). 
FS(p- tau231 and MMSE) additionally increased the sensitivity of differ-
entiation between AD vs HC and AD vs VaD, but not between VaD vs 
HC (Table 3).
4  | DISCUSSION
We analyzed the diagnostic value of specific biomarkers of the t- tau 
protein, p- tau231, and FS (made from p- tau231 and MMSE) in the dif-
ferentiation of patients with AD vs VaD group. The t- tau levels were 
significantly elevated in subjects with AD compared to HC. P- tau231 
levels were significantly higher in patients with AD vs HC as well in 
patients with VaD vs HC. There was no statistical significance of p- 
tau231 in distinguishing patients with AD vs VaD. When we exam-
ined FS (p- tau231 and MMSE), we received statistical significance 
for distinguishing patients with AD vs HC and patients with VaD vs 
HC. The most significant was the fact that FS (p- tau231 and MMSE) 
showed significant differences in the distribution of subjects with 
AD and VaD. Based on the Recommendations of a Consensus Report 
for Useful Biomarkers of AD, setting specificity and sensitivity to 85% 
or higher,13 our results indicate that p- tau231 shows specificity and 









Total tau (pg/ml) p- tau231 (U/ml)
Mean ± SD
Median (25- 75th 
percentile) Mean ± SD
Median (25- 75th 
percentile)
AD (152) 71 ± 8.0 83 vs 69 20.4 ± 4.4 532 ± 377 439 (257- 666.6) 3.501 ± 5.007 1.758 (0.805- 3.493)
HC (18) 59 ± 14.8 8 vs 10 28.5 ± 1.8 271 ± 265.9 185 (83.5- 334) 0.907 ± 1.481 0.587 (0.164- 0.803)
VaD (28) 70 ± 9.6 15 vs 13 22.6 ± 4.5 505 ± 314 429.8 (237.5- 692) 1.324 ± 0.704 1.098 (0.763- 1.905)
AD, Alzheimer’s disease; F, female; HC, healthy controls; M, male; MMSE, Mini- Mental State Examination; SD, standard deviation; VaD, vascular 
dementia.
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sensitivity greater than 75% in distinguishing subjects with AD vs HC 
(76.7% sensitivity and 77.8% specificity) while FS(p- tau231 and MMSE) 
shows 90% sensitivity in differentiating subjects with AD vs HC, but 
the specificity of this group is less than 75%. Similarly, p- tau231 differ-
entiates subjects for VaD vs HC with sensitivity 80% and specificity 
77.8%, and FS(p- tau231 and MMSE) shows sensitivity 80% and speci-
ficity 85%, which makes it an ideal candidate biomarker.
Vandermeeren and colleagues reported that t- tau was increased in 
patients with AD compared to HC, as confirmed by later studies.14,15 
Levels of t- tau were shown to be a marker of neural damage, increased 
not only in AD, but also in other primary causes of dementia.16 In addi-
tion, subsequent investigations have confirmed that t- tau levels in CSF 
reflect the intensity of neuronal damage and degeneration. Therefore, 
t- tau levels can also be elevated in patients with vascular damage,17 
whereas the highest values of the t- tau protein have been described 
F IGURE  1 Levels of p- tau231 in Alzheimer’s disease and vascular 
dementia patients, and healthy controls. Boxes represent the median, 
the 25th and 75th percentiles, and bars indicate the range of data 
distribution. Circles represent outliers, asterisks represent extreme 
data points
F IGURE  2 Levels of FS (p- tau231, MMSE) in Alzheimer’s disease 
and vascular dementia patients, and healthy controls. Boxes represent 
the median, the 25th, and 75th percentiles, and bars indicate the 
range of data distribution. Circles represent outliers, asterisks 
represent extreme data points
TABLE  2 Correlation between t- tau and p- tau231





All patients r = 0.251, df = 185, 
P = 0.001*
rS = 0.609, 
df = 185, 
P < 0.001*
AD (146) r = 0.211, df = 144, 
P = 0.011
rS = 0.543, 
df = 144, 
P < 0.001*
HC (18) r = 0.815, df = 16, 
P < 0.001*
rS = 0.272, df = 16, 
P = 0.275
VaD (20) r = 0.781, df = 18, 
P < 0.001*
rS = 0.772, df = 18, 
P < 0.001*
AD, Alzheimer’s disease; HC, healthy controls; MMSE, Mini- Mental State 
Examination; VaD, vascular dementia.
*P < 0.05.
F IGURE  3 Correlation between t- tau and p- tau231 levels
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in Creutzfeldt- Jakob’s disease due to a very intensive neuronal de-
generation.18 In one study, the transient increase in CSF t- tau con-
centration in acute stroke positively correlated with the area of brain 
infarction, measured by computerized tomography.17 Schönknecht 
et al19 showed that t- tau levels were significantly higher in patients 
with AD compared to VaD, as well as HC and patients suffering from 
major depression. Several other authors confirmed these results,20-22 
although other authors reported divergent data.23,24 Some factors 
may explain these differences. First, in acute stroke t- tau levels are 
increased in CSF, but the highest values have been observed only 
F IGURE  4 ROC curve analysis for p- tau231 between A) Alzheimer’s disease (AD) and healthy controls (HC), B) vascular dementia (VaD) and 
HC, and for FS (p- tau231, MMSE) between C) AD and HC, D) VaD and HC, and E) AD vs VaD













Sensitivity (%) 76.7 90.3 80 80 90.3
Specificity (%) 77.8 63.2 77.8 85 55
Cut-off 0.734 0.748 0.728 0.870 0.748
P <0.001* <0.001* <0.001* <0.001* 0.001*
AD, Alzheimer’s disease; FS, factor score; HC, healthy controls; MMSE, Mini- Mental State Examination; 
VaD, vascular dementia.
*P < 0.05.
TABLE  3 Sensitivity, specificity, cut-off 
levels, and P- values for p- tau231 and FS 
(p- tau231, MMSE) among examined groups
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3 weeks after stroke after which they gradually decreased over the 
next 3- 5 months.17 Second, elevated levels of t- tau in VaD observed 
in some studies may mean that some patients may have experienced 
repeated strokes during the follow- up period, but without any clinical 
signs, especially if there had been a preexisting history of neurological 
signs without significant changes in HIS score. Because neuroimaging 
is more frequently performed than lumbar puncture for diagnosis of 
VaD, clinicians should consider repeating neuroimaging before lumbar 
puncture in VaD patients.
According to several previous investigations, p- tau231 is a marker 
highly specific of AD.25-27 Thus, it can be detected very early in the 
CSF of patients with AD.25 The p- tau231 concentration alone has 
also shown a good correlation with the progression of the disease in 
a single patient with AD.25,26 Bürger and colleagues showed that p- 
tau231 levels were elevated in subjects with MCI and also inversely 
correlated with their MMSE score.27 Also, the data from Hampel and 
collaborators agree with the notion that variations in p- tau231 levels 
reflect differences in the degree of neuronal damage across AD pa-
tients. Although the strength of the correlations presently suggests no 
sufficient clinical utility to individual patients, p- tau231 levels may be 
used to predict progression of brain atrophy in AD.28 Hampel and col-
laborators demonstrated the discriminatory power of p- tau (p- tau231, 
p- tau181, p- tau199) in differentiating patients with AD from HC as well 
as other types of dementia including VaD.29 Unfortunately, due to in-
sufficient number of patients with VaD, the discriminatory (cut-off) 
levels of p- tau231 for VaD could not be demonstrated in that study.
29 
A longitudinal study of CSF tau protein in AD and VaD showed a sta-
tistically significant difference in the concentrations of t- tau and p- 
tau in AD (moderate to severe AD) compared to VaD, especially in 
the case of severe AD, but no significant differences in the levels of 
t- tau and p- tau231 as MMSE scores after 6 months of monitoring com-
pared to initial measurements.30 It should be noted that our study 
revealed similar results, whereas our patients generally had milder de-
mentia, as measured by MMSE scores, than the study of Wang and 
collaborators.30
The present study took care to match subject groups as closely as 
possible for age, sex, and other demographic characteristics, so that 
confounding biases could be minimized. Nevertheless, HC were on 
average younger than subjects from the other groups, which could 
have influenced the outcome to some level. We also had a relatively 
fewer HC. The possible discrepancies could also result from differ-
ences in study design. To verify the reliability of our results, we there-
fore performed all CSF analyses with at least two internal sample 
controls.
Previous studies have shown that p- tau231 CSF levels reliably dif-
ferentiate patients with AD and HC.31 Our results confirm and extend 
these observations, as they indicate that p- tau231 CSF levels can also 
be used for differentiating subjects with VaD from HC. Additionally, in 
distinguishing between AD and VaD, we established that FS (p- tau231 
and MMSE) has a strong potential to offer earlier distinction between 
these conditions. This finding has not only clinical significance, but 
also potential to prevent development and complications of VaD at 
an early stage.
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